GlassScriptPhysician profile
Bilal Ahmad
NPI 1275845778
$4,431.92
in general payments reported to CMS, 2019-2025
43 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $393 · 2021: $463 · 2022: $59.03 · 2023: $721 · 2024: $341 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $974 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $973.50 |
| Education | $262.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,147.64 | 2019-2025 | Imdelltra (Amg757), Lumakras |
| Pfizer INC. | $447.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $334.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $197.55 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $188.65 | 2019-2025 | Imfinzi |
| Eisai INC. | $156.99 | 2021-2023 | |
| Genzyme Corporation | $154.73 | 2019-2024 | |
| Johnson & Johnson Vision Care, INC. | $142.04 | 2021 | |
| Astellas Pharma US INC | $131.70 | 2019-2024 | Padcev |
| Sun Pharmaceutical Industries INC. | $122.53 | 2023 | Yonsa |
| E.R. Squibb & Sons, L.L.C. | $120.29 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $106.75 | 2019-2023 | Darzalex |
| Genentech USA, INC. | $106.61 | 2019-2023 | Tecentriq, Alecensa |
| Daiichi Sankyo INC. | $91.35 | 2019-2025 | Enhertu, Vanflyta |
| Gilead Sciences, INC. | $90.60 | 2023-2025 | Trodelvy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.